Your browser doesn't support javascript.
loading
Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.
Billington, John; Deschamps, Isabelle; Erck, Stanley C; Gerberding, Julie L; Hanon, Emmanuel; Ivol, Sabrina; Shiver, John W; Spencer, Julia A; Van Hoof, Johan.
Afiliação
  • Billington J; John Billington, JD, MPH, is Director, Science Policy, and Emmanuel Hanon, PhD, DVM, is Senior Vice President, Head of R&D; both at GSK Vaccines, Wavre, Belgium.
  • Deschamps I; Isabelle Deschamps, PhD, is Head of Global Vaccine Public Affairs; and John W. Shiver, PhD, is Senior Vice President R&D; both with Sanofi Pasteur, Lyon, France.
  • Erck SC; Stanley C. Erck, MBA, is President and Chief Executive Officer, Novavax, Gaithersburg, MD.
  • Gerberding JL; Julie L. Gerberding, MD, MPH, is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health; and Julia A. Spencer, PhD, is Associate Vice President, Global Public Policy; both with Merck & Co., Inc., Kenilworth, NJ.
  • Hanon E; John Billington, JD, MPH, is Director, Science Policy, and Emmanuel Hanon, PhD, DVM, is Senior Vice President, Head of R&D; both at GSK Vaccines, Wavre, Belgium.
  • Ivol S; Sabrina Ivol is Senior Specialist, Policy; and Johan Van Hoof, MD, is Managing Director; both with Janssen Vaccines & Prevention BV, Janssen Pharmaceuticals R&D, Leiden, Netherlands.
  • Shiver JW; Isabelle Deschamps, PhD, is Head of Global Vaccine Public Affairs; and John W. Shiver, PhD, is Senior Vice President R&D; both with Sanofi Pasteur, Lyon, France.
  • Spencer JA; Julie L. Gerberding, MD, MPH, is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health; and Julia A. Spencer, PhD, is Associate Vice President, Global Public Policy; both with Merck & Co., Inc., Kenilworth, NJ.
  • Van Hoof J; Sabrina Ivol is Senior Specialist, Policy; and Johan Van Hoof, MD, is Managing Director; both with Janssen Vaccines & Prevention BV, Janssen Pharmaceuticals R&D, Leiden, Netherlands.
Health Secur ; 18(3): 241-249, 2020.
Article em En | MEDLINE | ID: mdl-32348165
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Pneumonia Viral / Vacinas contra Influenza / Saúde Global / Tecnologia Farmacêutica / Infecções por Coronavirus / Doenças Transmissíveis Emergentes / Pandemias Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Health Secur Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Bélgica
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Pneumonia Viral / Vacinas contra Influenza / Saúde Global / Tecnologia Farmacêutica / Infecções por Coronavirus / Doenças Transmissíveis Emergentes / Pandemias Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Health Secur Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Bélgica